The conformation-selective PI3Kdelta inhibitor roginolisib in patients with advanced or metastatic cancer, including metastatic uveal melanoma: first-in-human clinical trial. (nature.com)

Authors: Di Giacomo AM … Maio M Journal: Nature Communications Published: 2026-10-09 DOI: https://doi.org/10.1038/s41467-026-77358-7